- Home
- ALTS vs CTSO Comparison
ALTS vs CTSO Comparison
Compare ALTS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- CTSO
- Stock Information
- Founded
- ALTS 1976
- CTSO 1997
- Country
- ALTS United States
- CTSO United States
- Employees
- ALTS N/A
- CTSO N/A
- Industry
- ALTS
- CTSO Medical/Dental Instruments
- Sector
- ALTS
- CTSO Health Care
- Exchange
- ALTS NYSE
- CTSO Nasdaq
- Market Cap
- ALTS 66.5M
- CTSO 61.3M
- IPO Year
- ALTS N/A
- CTSO N/A
- Fundamental
- Price
- ALTS $4.33
- CTSO $1.02
- Analyst Decision
- ALTS
- CTSO Strong Buy
- Analyst Count
- ALTS 0
- CTSO 3
- Target Price
- ALTS N/A
- CTSO $4.67
- AVG Volume (30 Days)
- ALTS 140.9K
- CTSO 85.6K
- Earning Date
- ALTS 03-28-2025
- CTSO 05-08-2025
- Dividend Yield
- ALTS N/A
- CTSO N/A
- EPS Growth
- ALTS N/A
- CTSO N/A
- EPS
- ALTS N/A
- CTSO N/A
- Revenue
- ALTS $12,532,000.00
- CTSO $37,739,531.00
- Revenue This Year
- ALTS N/A
- CTSO $9.20
- Revenue Next Year
- ALTS N/A
- CTSO $11.64
- P/E Ratio
- ALTS N/A
- CTSO N/A
- Revenue Growth
- ALTS N/A
- CTSO 1.80
- 52 Week Low
- ALTS $1.29
- CTSO $0.70
- 52 Week High
- ALTS $7.75
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- ALTS 35.93
- CTSO 44.01
- Support Level
- ALTS $3.84
- CTSO $0.97
- Resistance Level
- ALTS $4.58
- CTSO $1.08
- Average True Range (ATR)
- ALTS 0.42
- CTSO 0.07
- MACD
- ALTS -0.05
- CTSO -0.01
- Stochastic Oscillator
- ALTS 4.58
- CTSO 17.53
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.